The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients

Basit Öğe Kaydı
dc.contributor.authorTarighi, Bahman
dc.contributor.authorKurum, Turhan
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorAzcan, Sen Nur
dc.date.accessioned2024-06-12T11:01:54Z
dc.date.available2024-06-12T11:01:54Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBACKGROUND: The aim of the present study was to investigate the effects of nebivolol (5 mg daily) on plasma levels of hemostatic and fibrinolytic endothelial function markers in mild or moderate hypertensive patients. METHODS AND RESULTS: Thirty-five (22 female, 13 male; mean +/- SD 54.7 +/- 11.3 years of age) mild and moderate hypertensive patients were included the study. The mean systolic blood pressure [BP] was 160 mmHg (range 150 mmHg to 165 mmHg) and the mean diastolic BP was 100 mmHg (range 90 mmHg to 100 mmHg). Plasma tissue plasminogen activator antigen (tPA-Ag), plasminogen activator inhibitor type 1 antigen (PAI-1-Ag), PAI-1-activity, tPA-Ag/PAI-1-Ag index, fibrinogen and euglobulin lysis time were determined before and after two months of therapy. tPA-Ag and PAI-Ag levels were measured by ELISA. After this period, treatment with nebivolol (5 mg/day) in all patients was associated with a significant decrease in systolic BP and diastolic BP (P < 0.001 for each), heart rate (P < 0.01), fibrinogen (P < 0.005) and euglobutin lysis time (P < 0.01). The tPA-Ag and tPA-Ag/PAI-1-Ag index levels were increased significantly (P < 0.001 for each) in all patients, but the PAI-1-Ag (P > 0.05) and PAI-1 activity (P > 0.05) did not show significant change. In the present study, there was no correlation between decreases in arterial BP and decreases in fibrinolytic parameters (P > 0.05), but there was a positive, statistically significant correlation between fibrinogen and body mass index (P < 0.001). CONCLUSIONS: The results indicated that, compared with no treatment, a two-month treatment trial with nebivolol was associated with a more favourable modification of hemostatic and fibrinolytic status in addition to antihypertensive effects.en_US
dc.identifier.doi10.1016/S0828-282X(07)70227-1
dc.identifier.endpage655en_US
dc.identifier.issn0828-282X
dc.identifier.issue8en_US
dc.identifier.pmid17593991en_US
dc.identifier.scopus2-s2.0-34547540683en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage651en_US
dc.identifier.urihttps://doi.org/10.1016/S0828-282X(07)70227-1
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21074
dc.identifier.volume23en_US
dc.identifier.wosWOS:000247454100006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPulsus Group Incen_US
dc.relation.ispartofCanadian Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFibrinolytic Systemen_US
dc.subjectHypertensionen_US
dc.subjectNebivololen_US
dc.subjectPlasminogen-Activator Inhibitoren_US
dc.subject3rd-Generation Beta-Blockeren_US
dc.subjectMyocardial-Infarctionen_US
dc.subjectHemostatic Factorsen_US
dc.subjectBlood-Pressureen_US
dc.subjectAntihypertensive Treatmenten_US
dc.subjectEndothelial Dysfunctionen_US
dc.subjectSystemic Hypertensionen_US
dc.subjectProthrombotic Stateen_US
dc.subjectPlasma-Fibrinogenen_US
dc.titleThe effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu